The ANKEF1 Knockout HeLa Polyclonal Cells constitute a heterogeneous CRISPR/Cas9-mediated gene-disrupted population targeting the human ANKEF1 locus in HeLa cells. This polyclonal knockout pool, derived from bulk editing and selection, retains diverse genetic alterations without clonal isolation, making it suitable for loss-of-function studies in a physiologically relevant cellular context. The product is intended for advanced biomedical research applications requiring manipulation of calcium/calmodulin-dependent signaling networks.
HeLa cells, originating from a human cervical adenocarcinoma, are an established epithelial model system expressing human papillomavirus type 18 E6 and E7 oncoproteins. These oncoproteins inactivate the tumor suppressors p53 and pRb, respectively, endowing HeLa with immortality and dysregulated cell cycle control. Consequently, HeLa serves as a robust platform for cancer biology, cell signaling, apoptosis, and drug discovery research. Their ease of culture and genetic manipulation facilitates functional genomics studies using CRISPR/Cas9 technology.
ANKEF1 encodes a multidomain scaffold protein containing ankyrin repeats and EF-hand motifs, functioning as a calcium sensor that undergoes calcium-dependent conformational changes to bind calmodulin (CALM1, CALM2, CALM3). This interaction recruits protein phosphatases and likely activates calmodulin-dependent kinases such as CaMKII and calcineurin, which are representative components of the Ca2?/calmodulin signaling axis. ANKEF1 is thought to link calcium influx to cytoskeletal organization, possibly by scaffolding ankyrin repeat-containing proteins and downstream cytoskeletal effectors. In the calcium signaling pathway, ANKEF1 acts upstream of CAMKs, modulating cellular responses through calmodulin-mediated transduction.
In the HeLa context, calcium signaling governs proliferation, migration, and apoptosis, often via calmodulin-dependent pathways. Disruption of ANKEF1 in this polyclonal pool enables researchers to probe how Ca2?/calmodulin scaffolding influences cytoskeletal dynamics and cell fate decisions. Given the oncogenic background of HeLa cells, this knockout model may also reveal connections between calcium-dependent scaffolds and pathways dysregulated in cervical adenocarcinoma, including potential roles in ciliopathy-related phenotypes or tumor suppression. The model provides a tool to dissect functional interactions between ANKEF1 and calmodulin-regulated networks in an epithelial cancer setting.
Key applications of ANKEF1 Knockout HeLa Polyclonal Cells span investigation of calcium signaling mechanisms, ankyrin repeat-mediated protein?Cprotein interactions, and cell cycle or apoptosis regulation. Compatible experimental approaches include co-immunoprecipitation of ANKEF1 with calmodulin, live-cell calcium imaging using Fluo-4, immunofluorescence labeling of cytoskeletal components, Western blotting for phosphorylated CaMKII, and flow cytometry for cell cycle distribution or Annexin V positivity. These cells are also suitable for small-molecule screening targeting calmodulin interactions. For more information, please contact Ascent Research.
